Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
about
Polyunsaturated fatty acid metabolism in prostate cancerMultiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancerPlatelet effects on ovarian cancerMechanisms of omega-3 polyunsaturated fatty acids in prostate cancer preventionEpigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequencesTumor stroma as targets for cancer therapyPharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesisInterleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.Glucocorticoid-induced reversal of interleukin-1β-stimulated inflammatory gene expression in human oviductal cells.3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis.Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation.Platelets and cancer: a casual or causal relationship: revisited.Tolerance of neurite outgrowth to Rho kinase inhibitors decreased by cyclooxygenase-2 inhibitor.Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression.Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancerCelecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells.Lung cancer chemoprevention with celecoxib in former smokers.Innate inflammation and cancer: Is it time for cancer prevention?Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland.Prostaglandins in cancer cell adhesion, migration, and invasionEfficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.Association between 8473T>C polymorphism in the cyclooxygenase-2 gene and the risk of nasopharyngeal carcinoma.n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention.COX-2 dependent regulation of mechanotransduction in human breast cancer cellsMicroRNA and AU-rich element regulation of prostaglandin synthesisGrowth and adherence of Staphylococcus aureus were enhanced through the PGE2 produced by the activated COX-2/PGE2 pathway of infected oral epithelial cells.Thyroid Cancer and Nonsteroidal Anti-Inflammatory Drug Use: A Pooled Analysis of Patients Older Than 40 Years of AgeThe Chemistry and Biology of Nakiterpiosin - C-nor-D-Homosteroids.The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.Non-steroid anti-inflammatory drugs, prostaglandins, and cancer.Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs.Protein Markers Predict Survival in Glioma Patients.Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
P2860
Q24629893-C458B347-4FA6-4C2D-966F-FA6E8F8C9D84Q26828414-4F9DDBF4-E15A-488F-B074-AAFFEF619C5DQ26829401-9001B280-4906-4704-A05C-C037EF20ADA1Q26830150-2F861868-95EF-4236-A456-E099251AC13EQ26862642-1ECF4ECB-C00F-41BC-B760-AAA80EC5F6E2Q27015980-42B7D816-A451-474C-885E-38F29CD77F75Q28481397-F75A401B-CE6A-40CC-B405-6C5876F96623Q33565624-E80452A1-CA3B-4835-ABD2-934BB63B7E53Q33645478-7A16F761-EA7C-47ED-87C4-5AF92A6003D2Q33920786-364FDCD0-37F6-4D6E-BE7E-E2BEE8BB1828Q34041458-6202631B-A217-4525-92A7-C7FFFAA6ED5AQ34206376-5752962B-F745-489D-8747-7512CE551CA5Q34206458-58295192-5FF4-4078-9E36-939085870D3DQ34294719-7B8A1753-3BC5-4754-9F6B-E92A56461117Q34358302-0E793F01-7E6C-474E-BDD5-42AB650ADAC1Q34408525-A6663412-8408-4ADA-A6D4-DA04A22C889EQ34462187-E00B4179-04F4-442D-9AFD-F91075D73635Q34733346-DC9C83FE-FA9C-40FA-8F43-07178B4DCBC7Q35069917-4743D7CF-D671-48F1-9EFB-E8052A1FA18EQ35156358-008F0033-FE0E-437B-93D7-F493B5208292Q35161634-6660B409-3039-4115-A3F2-E7978A760030Q35220347-1E492CAC-93DC-4AE2-8927-D1EF6BE5C6EAQ35285768-CC4919C8-5AC9-492B-87CC-0C9699B37436Q35542920-E65335C9-DB15-4736-BBD6-E1F231A3C9B4Q35821653-B831E679-471E-4077-9ADF-EE3A5C44429AQ35846025-4D59E25D-E632-4F7D-B1BC-F67E3E6A1829Q35919516-3546C4AF-CECD-48C0-956A-D976428C16E6Q36131716-E74F4BF9-8F0F-42D6-9219-15E63D893F9BQ36214324-6CC2BAC1-F73B-48C5-86E6-294BCC2AFE08Q36249379-8DEA74D6-E19A-46B6-86A1-153D181A89D9Q36363166-9150EDCA-7C62-4B99-80D1-3FD42E05CD08Q36385997-461756FD-B609-460C-B64C-AD44052DEC66Q36447545-A98EE1CF-0C68-422A-B569-3AD239CD49C1Q36492336-9FF85A5E-B595-4BD8-88E3-CC406D97ABE4Q36573214-43E2DEAC-789A-4EA3-8E37-A01ED729EB54Q36689177-C33FAC6C-A04E-41BD-9F70-599812EC0F9AQ36806255-836F675D-8EA9-4A0A-B641-87042E514A50Q36813986-602F2DDF-7EBF-42B6-8FC8-F9C5C1253F38Q37076888-F53AC6D7-3E75-4A0B-831B-AA8AB8E45F4FQ37111529-4E364A95-8399-4527-9AD3-5FA8FC891B49
P2860
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@ast
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@en
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@nl
type
label
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@ast
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@en
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@nl
prefLabel
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@ast
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@en
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@nl
P2093
P2860
P3181
P1476
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward
@en
P2093
David G Menter
Raymond N DuBois
Richard L Schilsky
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-09-0788
P407
P577
2010-03-01T00:00:00Z